Zydelig (idelalisib) has been approved in combination with Rituxan for the treatment of relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients who have had at least two prior systemic therapies.
Thursday, July 24, 2014
Sunday, July 13, 2014
Belinostat for T-cell lymphoma
Belinostat (Beleodaq) has now been approved for relapsed or refractory T-cell lymphoma.
Subscribe to:
Posts (Atom)